ClinVar Miner

Submissions for variant NM_000179.3(MSH6):c.3477C>A (p.Tyr1159Ter)

dbSNP: rs398123231
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 12
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Eurofins Ntd Llc (ga) RCV000078315 SCV000110159 pathogenic not provided 2013-06-07 criteria provided, single submitter clinical testing
Invitae RCV000456684 SCV000551165 pathogenic Hereditary nonpolyposis colorectal neoplasms 2023-12-01 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Tyr1159*) in the MSH6 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH6 are known to be pathogenic (PMID: 18269114, 24362816). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with Lynch syndrome-associated cancers (PMID: 21642682, 21868491). ClinVar contains an entry for this variant (Variation ID: 92577). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic.
Ambry Genetics RCV000491158 SCV000580185 pathogenic Hereditary cancer-predisposing syndrome 2022-05-19 criteria provided, single submitter clinical testing The p.Y1159* pathogenic mutation (also known as c.3477C>A), located in coding exon 6 of the MSH6 gene, results from a C to A substitution at nucleotide position 3477. This changes the amino acid from a tyrosine to a stop codon within coding exon 6. This mutation was identified in a single French family suspected of Lynch syndrome in one study (Bonadona V et al. JAMA 2011 Jun;305:2304-10). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV002265599 SCV000919761 pathogenic Hereditary nonpolyposis colon cancer 2022-05-02 criteria provided, single submitter clinical testing Variant summary: MSH6 c.3477C>A (p.Tyr1159X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 251396 control chromosomes. c.3477C>A has been reported in the literature in individuals affected with Lynch Syndrome (example, Bonadona_2011, Perez-Carbonell_2011, Marignol_2008, Rey_2017, Ferrer-Avargues_2021, Post_2021). These data indicate that the variant is likely to be associated with disease. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Color Diagnostics, LLC DBA Color Health RCV000491158 SCV001340971 pathogenic Hereditary cancer-predisposing syndrome 2020-01-15 criteria provided, single submitter clinical testing This variant changes 1 nucleotide in exon 6 of the MSH6 gene, creating a premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of MSH6 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic.
GeneDx RCV000078315 SCV002102639 pathogenic not provided 2022-02-28 criteria provided, single submitter clinical testing Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Observed in individuals with a personal or family history consistent with pathogenic variants in this gene (Bonadona 2011, Prez-Carbonell 2012); Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 21642682, 21868491, 28502729, 32719484)
Genetics and Molecular Pathology, SA Pathology RCV002272057 SCV002556696 likely pathogenic Lynch syndrome 2021-07-01 criteria provided, single submitter clinical testing
Myriad Genetics, Inc. RCV003453005 SCV004188308 pathogenic Lynch syndrome 5 2023-08-23 criteria provided, single submitter clinical testing This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation.
Baylor Genetics RCV003466970 SCV004195571 pathogenic Endometrial carcinoma 2023-08-21 criteria provided, single submitter clinical testing
Mayo Clinic Laboratories, Mayo Clinic RCV000078315 SCV000257257 pathogenic not provided no assertion criteria provided research
Constitutional Genetics Lab, Leon Berard Cancer Center RCV001249964 SCV001423978 pathogenic Lynch-like syndrome 2019-07-01 no assertion criteria provided clinical testing
Department of Pathology and Laboratory Medicine, Sinai Health System RCV001354656 SCV001549322 likely pathogenic Carcinoma of colon no assertion criteria provided clinical testing The MSH6 p.Tyr1159* variant was identified in 2 of 5260 proband chromosomes (frequency: 0.0004) from individuals or families with colon cancer (Bonadona 2011, Perez-Cabornell 2011). The variant was also identified in dbSNP (ID: rs398123231) as “With Pathogenic, Uncertain significance allele"), ClinVar (classified as pathogenic by Invitae, Ambry Genetics, and two other clinical laboratories), UMD-LSDB (12x as causal), and in Insight InSiGHT Hereditary Tumors databases. The variant was not identified in the COGR, Cosmic, MutDB, Zhejiang University Database, and or Mismatch Repair Genes Variant databases. The variant was not identified in the following control databases: the 1000 Genomes Project, the NHLBI GO Exome Sequencing Project, the Exome Aggregation Consortium (August 8th 2016), or the Genome Aggregation Database (Feb 27, 2017). The p.Tyr1159* variant leads to a premature stop codon at position 1159, which is predicted to lead to a truncated or absent protein and loss of function. Loss of function variants of the MSH6 gene are an established mechanism of disease in Lynch syndrome and this is the type of variant expected to cause the disorder. In summary, based on the above information this variant meets our laboratory’s criteria to be classified as pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.